Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

DISEASE CHARACTERISTICS:

Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity carcinoma

Recurrent or persistent disease
Measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest dimension to be recorded) ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan

Must have at least 1 "target lesion" to be used to assess response on this protocol as defined by RECIST criteria

Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy

Must have had 1 prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound and the initial treatment may have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment

Patients are allowed, but not required to receive, 2 additional cytotoxic regimens for management of recurrent or persistent disease with no more than 1 non-platinum, non-taxane regimen

Patients who have received only 1 prior cytotoxic regimen (platinum-based regimen for management of primary disease), must meet 1 of the following criteria:

Platinum-free interval of < 12 months
Progressed during platinum-based therapy
Persistent disease after a platinum-based therapy
Not eligible for a higher priority GOG protocol (i.e., any active GOG Phase III protocol for the same patient population)

PATIENT CHARACTERISTICS:

GOG performance status (PS) 0-2 or after receiving 1 prior treatment regimen (GOG PS 0-1 after receiving 2 or more prior regimens)
Platelet count ≥ 100,000/mm³
ANC count ≥ 1,500/mm³
Hemoglobin > 9 g/dL
Creatinine ≤ 1.5 times upper limit normal (ULN)
AST and ALT ≤ 2.5 times ULN
CPK normal
Bilirubin or direct bilirubin normal
Alkaline phosphatase normal
Neuropathy (sensory and motor) ≤ grade 1
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No active infection requiring antibiotics (except for uncomplicated UTI)
No other invasive malignancy within the past 5 years, except nonmelanoma skin cancer
No known active liver disease or hepatitis
Willing and able to have a central venous catheter

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Recovered from effects of recent surgery, radiotherapy, or chemotherapy

At least 1 week since prior hormonal therapy directed at the malignant tumor

Continuation of hormone replacement therapy allowed
At least 3 weeks since other prior therapy, including biological and immunological therapy directed at the tumor
Chimeric or human or humanized monoclonal antibodies must be discontinued for at least 6 weeks prior to study entry
No investigational therapy within the past 30 days
No prior therapy with docetaxel and/or trabectedin
No radiation to more than 25% of marrow-bearing areas
No prior cancer treatment that contraindicates protocol therapy